share_log

GSK's Respiratory Syncytial Virus Vaccine Given Together With Shingles Shot Shows Non-Inferior Immune Response In Older Adults

GSK's Respiratory Syncytial Virus Vaccine Given Together With Shingles Shot Shows Non-Inferior Immune Response In Older Adults

GSK的呼吸道合胞病毒疫苗與帶狀皰疹疫苗一起接種在老年人中顯示非劣性免疫應答
Benzinga ·  2024/09/18 14:01

Wednesday, GSK plc (NYSE:GSK) released topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, reactogenicity and safety of Arexvy (Respiratory Syncytial Virus Vaccine) when co-administered with Shingrix (Zoster Vaccine).

週三,GSk公司(紐交所:GSK)發佈了成人50歲及以上的3期試驗頂線數據,評估了Arexvy(呼吸道合胞病毒疫苗)與Shingrix(帶狀皰疹疫苗)聯合接種時的免疫原性、反應原性和安全性。

  • Shingrix is approved to prevent shingles (herpes zoster) in adults aged 50 and older.
  • Arexvy is approved for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older and in individuals 50 through 59 who are at increased risk for LRTD caused by RSV.
  • Shingrix已獲得批准,用於預防50歲及以上成年人的帶狀皰疹(皰疹性帶狀皮炎)。
  • Arexvy已獲得批准,用於預防60歲及以上的個體以及50至59歲的有增加患呼吸道合胞病毒引起的下呼吸道疾病風險的個體的下呼吸道疾病(LRTD)。

The data were presented as a late-breaking abstract at the European Geriatric Medicine Society (EuGMS) Congress.

這些數據作爲一份遲到的摘要報告在歐洲老年醫學學會(EuGMS)大會上呈報。

Also Read: GSK Halts Herpes Simplex Virus Vaccine Development, Clears Path For Other Contenders Like Moderna, BioNTech.

此外閱讀:GSK停止研發單純皰疹病毒疫苗,爲Moderna、BioNTech等其他競爭者鋪平道路。

The data showed a non-inferior immune response when the vaccines were co-administered compared to when they were administered at separate visits.

數據顯示在聯合接種疫苗與分開接種疫苗的情況下,免疫反應非劣效。

Co-administration was also well tolerated, with acceptable reactogenicity and safety profiles.

聯合接種也很耐受,具有可接受的反應原性和安全性。

In both groups, the most frequently reported adverse events were pain at the injection site, fatigue, and myalgia.

在兩個組中,最常報告的不良事件是注射部位疼痛、疲勞和肌痛。

The duration of solicited adverse events was comparable across the two groups.

兩組受訪者報告的不良事件持續時間相當。

Results from this trial will be submitted for peer-reviewed scientific publication and will be used to support regulatory submissions to the FDA, the European Medicines Agency, and other regulators.

該試驗結果將被提交給同行評議的科學出版物,並用於支持向FDA、歐洲藥品管理局和其他監管機構提交的申請。

Each year, approximately 177,000 adults 65 years and older are hospitalized in the US due to RSV, and an estimated 14,000 of those cases result in death.

每年大約有17.7萬名65歲及以上的成年人因RSV而在美國住院,估計其中有1.4萬例導致死亡。

Shingles is a painful, blistering rash caused by the reactivation of the varicella-zoster virus (VZV)—the same virus that causes chickenpox. An estimated one million people develop shingles annually in the US.

帶狀皰疹是由水痘-帶狀皰疹病毒(VZV)重新激活引起的疼痛、起水皰的皮疹,這是引起水痘的同一種病毒。據估計,每年有一百萬人在美國患上帶狀皰疹。

The GSK proprietary AS01 adjuvant system contains QS-21 STIMULON adjuvant licensed from Antigenics Inc, a wholly owned subsidiary of Agenus Inc (NASDAQ:AGEN).

GSK專有的AS01佐劑系統含有Antigenics Inc.的QS-21 STIMULON佐劑,Antigenics Inc.是Agenus Inc(納斯達克:AGEN)的全資子公司。

Price Action: GSK stock is up 0.59% at $42.81 at the last check on Wednesday.

股價走勢:GSK股價上漲0.59%,報42.81美元,在週三最後一次查詢時。

  • Used Car Seller Carvana On Road To $15B Revenue By 2025 As Unit Growth Accelerates: BofA.
  • 二手車銷售商carvana計劃到2025年達到150億美元的營業收入,隨着銷售額增長加速:美國銀行。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
評論 評論 · 瀏覽 367

熱點推薦

搶先評論

聲明

本頁的譯文內容由軟件翻譯。富途將竭力但卻不能保證翻譯內容之準確和可靠,亦不會承擔因任何不準確或遺漏而引起的任何損失或損害。